The National Pharmaceutical Pricing Authority (NPPA) may fix the retail price of formulations that are under phase IV clinical trials based on the company's application submitted to the central drug regulator for conducting the phase of clinical trials and other documents included with the relevant form.

The Authority deliberated the issue of the retail price fixation of drugs under phase IV clinical trials after it received applications from the companies.

Considering that the matter involves the approval of the drug regulator, the authority took the view of the representative of Central Drugs Standard Control Organisation (CDSCO) into consideration.

Click for more articles on NPPA

A K Pradhan, joint drug controller, CDSCO, clarified to the authority that the phase IV clinical trials are to be conducted by the companies for the drugs that are classified as 'D' category drugs by the Kokate Committee and the drugs are in the market as per the approval of state licensing authorities (SLA), hence the companies need to apply to the Drugs Controller General (India) for permission to conduct phase IV clinical trial.

The Kokate Committee, which investigated the safety and efficacy of fixed-dose combinations (FDCs) approved by state drug regulators but falling under the definition of new drugs and lacking central drug regulator approval, classified the FDCs into four categories.

Click for more on Kokate Committee

Also read about other committees

DCC

DTAB

Technical Committee

Hathi Committee

Mashelkar Committee

The Category D, according to this, are the FDCs which require further generation of data for confirming the safety and efficacy.

The official said that a No Objection Certificate (NOC) is issued by the drug regulator subject to fulfillment of certain conditions by the company.

However, since the drug is already approved by SLA and has to be in market, the retail price may be fixed by the NPPA based on the copy of application submitted to DCGI for conducting phase IV Clinical Trials, or the NOC issued by the DCGI, or the license issued by the central drug regulator, along with the Form I.

Click for more articles on Clinical trials

The Form I, according to the DPCO, 2013, is an application for price fixation or revision of a new drug formulation related to the formulations in the National List of Essential Medicines (NLEM).

The particular form seeks data on the formulation, its manufacturer or importer, details of the approval from the drug regulatory authorities, package size, and retail price claimed for approval, reason for submission of application for price fixation or revision, among others.

Click for List of approved FDCs (Fixed Dose Combinations) Updated

It may be noted that the drug price regulator has been in the process of revising the ceiling prices of scheduled formulations listed in the Schedule I of the DPCO, 2013, after it has revised the Schedule replacing the National List of Essential Medicines (NLEM), 2015 with the latest NLEM, 2022.

The total unique formulations for which ceiling prices are to be fixed are around 819 and it has already notified prices of 119 formulations and approved 97 ceiling price calculations till the end of December, 2022.

Forms: Clinical Trial

Schedules: Clinical Trials

Notifications: New Drugs, FDC, Clinical Trial  

Other details about New Drugs, FDCs, Clinical trial    

FAQs by CDSCO on Pharma, Cosmetics, MDR, Clinical Trial

Latest on National Pharmaceutical Pricing Authority (NPPA)

Latest notifications – DPCO / NPPA

NPPA updated price lists: Download

Latest Notifications: EC Act (Essential Commodities Act)

FAQs – On DPCO: Drugs (Prices Control) Order, 2013

National List of Essential Medicines (NLEM)

Govt Job: For the post of Director at CDTL, CDSCO

List of approved FDCs (Fixed Dose Combinations) Updated

List of approved New Drugs Updated

NPPA extends ceiling price of LMO, Oxygen Inhalation

Drug recall: Daptomycin for Injection recalled due to this reason

New BCG vaccine for TB: Clinical trials to start soon

Drug licences of these two firms suspended: FDA Manipur

Fake pharma firm busted, two arrested

USFDA approves Fesoterodine Fumarate Extended-Release tablets

Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/2023/01/09/nppa-may-fix-retail-price-of-drugs-under-phase-iv-clinical-trials/